Entrada Therapeutics

Yahoo Finance • last month

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 2 months ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees under the Com... Full story

Yahoo Finance • 4 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics, Inc. BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan H... Full story

Yahoo Finance • 8 months ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenn... Full story

Yahoo Finance • 9 months ago

Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading

Entrada Therapeutics Inc (NASDAQ:TRDA [https://www.chartmill.com/stock/quote/TRDA]) reported its second-quarter 2025 financial results, missing analyst estimates on both revenue and earnings per share (EPS). The company posted revenue of $... Full story

Yahoo Finance • 9 months ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activ... Full story

Yahoo Finance • 10 months ago

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

Director Kush Parmar reported selling shares of Entrada Therapeutics , Inc. (NASDAQ:TRDA) on July 9, 2025. The sales involved 27,000 shares of common stock, netting approximately $202,554. The transaction comes as the stock trades near it... Full story

Yahoo Finance • 10 months ago

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

5AM Ventures V, a ten percent owner in Entrada Therapeutics , Inc. (NASDAQ:TRDA), a $238.33 million market cap biotech company, reported selling 27,000 shares of common stock on July 9, 2025. The transaction comes as the stock trades near... Full story

Yahoo Finance • 10 months ago

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

A group of Entrada Therapeutics , Inc. (NASDAQ:TRDA) ten percent owners, including 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., reported selling shares of common stock worth approximately $866632. The sales occurred between June 27... Full story

Yahoo Finance • 11 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- E... Full story

Yahoo Finance • 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold... Full story

Yahoo Finance • 2 years ago

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s Duchenne franchise with the selection of i... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-thera... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutic... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a n... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a n... Full story

Yahoo Finance • 3 years ago

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis i... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 - - Actively working to resolve the clinical hold on its IND application fo... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing End... Full story

Yahoo Finance • 3 years ago

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

- Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeut... Full story